LEXINGTON, Mass., Feb. 27, 2018 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology
company devoted to development of next-generation medicines to
improve the lives of patients with inflammatory diseases, today
announced that it has entered into a collaborative research
agreement with Janssen Research & Development, LLC (Janssen),
one of the Janssen Pharmaceutical Companies of Johnson &
Johnson. The agreement was facilitated by Johnson & Johnson
Innovation LLC.
Aldeyra plans to collaborate with Janssen on the development of
novel drugs designed to sequester pro-inflammatory aldehyde
mediators, a new class of therapeutic targets. Aldeyra's aldehyde
sequestration platform represents a novel therapeutic class, led by
reproxalap, a first-in-class drug candidate that has demonstrated
anti-inflammatory activity in four Phase 2 clinical trials. The
agreement is intended to advance the development of existing
analogs of reproxalap for the treatment of systemic inflammatory
diseases.
"As we are committed to the development of novel therapeutic
product candidates for autoimmune and other diseases characterized
by systemic inflammation, we are pleased to partner with Janssen, a
world leader in the discovery and development of therapeutics for
inflammatory diseases," commented Todd C.
Brady, M.D., Ph.D., President and CEO of Aldeyra.
Pursuant to the terms of the agreement, Aldeyra will collaborate
with Janssen on research activities, which will be governed by a
joint scientific review committee. For a limited period, subject to
certain conditions, Janssen will retain an option to negotiate an
exclusive license pertaining to compounds developed during the
collaboration.
About Aldeyra Therapeutics
Aldeyra Therapeutics is developing a next-generation medicines
to improve the lives of patients with inflammatory diseases.
Aldeyra's lead product candidate, reproxalap, is a first-in-class
treatment in late-stage development for dry eye disease and other
forms of ocular inflammation. The company is also developing other
product candidates for systemic inflammatory disease. Aldeyra
intends to commercialize its products directly and through
collaborations that expand global reach. None of Aldeyra's
product candidates have been approved for sale in the U.S. or
elsewhere.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding Aldeyra's plans and expectations
with respect to the collaboration or potential licenses with
Jassen. Aldeyra intends such forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995.
In some cases, you can identify forward-looking statements by terms
such as "may," "might," "will," "objective," "intend," "should,"
"could," "can," "would," "expect," "believe," "anticipate,"
"project," "target," "design," "estimate," "predict," "potential,"
"aim," "plan" or the negative of these terms, and similar
expressions intended to identify forward-looking statements. Such
forward-looking statements are based upon current expectations that
involve risks, changes in circumstances, assumptions and
uncertainties. Aldeyra is at an early stage of development and may
not ever have any products that generate significant revenue.
Important factors that could cause actual results to differ
materially from those reflected in Aldeyra's forward-looking
statements include, among others, the timing of enrollment,
commencement and completion of Aldeyra's clinical trials, the
timing and success of preclinical studies and clinical trials
conducted by Aldeyra and its development partners; updated or
refined data based on Aldeyra's continuing review and quality
control analysis of clinical data, Aldeyra's ability to design
clinical trials with protocols and endpoints acceptable to
applicable regulatory authorities, the ability to obtain and
maintain regulatory approval to conduct clinical trials and to
commercialize Aldeyra's product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs of
developing and commercializing Aldeyra's product candidates; the
size and growth of the potential markets for Aldeyra's product
candidates and the ability to serve those markets; Aldeyra's
expectations regarding Aldeyra's expenses and revenue, the
sufficiency of Aldeyra's cash resources and needs for additional
financing; the rate and degree of market acceptance of any of
Aldeyra's product candidates; Aldeyra's expectations regarding
competition; Aldeyra's anticipated growth strategies; Aldeyra's
ability to attract or retain key personnel; Aldeyra's ability to
establish and maintain development partnerships; Aldeyra's
expectations regarding federal, state and foreign regulatory
requirements; regulatory developments in the United States and foreign countries;
Aldeyra's ability to obtain and maintain intellectual property
protection for its product candidates; the anticipated trends and
challenges in Aldeyra's business and the market in which it
operates; and other factors that are described in the "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" sections of Aldeyra's Annual
Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form
10-Q for the quarter ended September 30,
2017, which are on file with the Securities and Exchange
Commission(SEC) and available on the SEC's website at www.sec.gov.
Additional factors may be described in those sections of Aldeyra's
Annual Report on Form 10-K for the year ended December 31, 2017, expected to be filed with the
SEC in the first quarter of 2018. All of Aldeyra's
development timelines may be subject to adjustment depending on
recruitment rate, regulatory review, preclinical and clinical
results, and other factors that could delay the initiation or
completion of clinical trials.
In addition to the risks described above and in Aldeyra's other
filings with the SEC, other unknown or unpredictable factors also
could affect Aldeyra's results. No forward-looking statements can
be guaranteed and actual results may differ materially from such
statements. The information in this release is provided only as of
the date of this release, and Aldeyra undertakes no obligation to
update any forward-looking statements contained in this release on
account of new information, future events, or otherwise, except as
required by law.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-agreement-with-johnson--johnson-innovation-to-advance-novel-immune-modulating-drugs-for-systemic-inflammatory-diseases-300604526.html
SOURCE Aldeyra Therapeutics, Inc.